Clinical effect of Atenativ treatment on uterine blood flow and the amount of Atenativ needed to maintain a normal antithrombin level during two weeks in early and severe preeclampsia

department of OBstetrics, Sahlgrenska university hospital0 个研究点开始时间: 2012年12月27日最近更新: 2013年4月22日

试验速览

暂无简介。

•Women with severe early-onset preeclampsia during gestational week 23-29+0.
•2. Severe preeclampsia as defined by international criteria (1,2)
•Blood pressure >160/110 mmHg (measured twice 30 minutes apart).
•proteinuria (>5 .0 g/L per 24 hours or >3 + labstick in at least two random
•samples six hours apart) after 20th gestational week.
•Blood pressure >140/90 mmHg and proteinuria >5.0 g/24 h.
•preeclampsia ( blood pressure > 140/90 and proteinuria >0.3 g/24 h) with IUGR or subjective symptoms as epigastic pain (HELLP), headache, dizziness or visual disturbancies, oligouri < 600 ml/24 h, coagulation disturbancies.
•3. AT level <0.8 kIE/LC
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 6
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.History of congenital AT deficiency
•2.Severe preeclampsia with demand on acute delivery within 24 hours according to the investigators judgement
•3.Concomitant administration of anticoagulants and platelet inhibitors within 2 weeks
•4.Chronic renal disease
•5.Diabetes melittus or gestational diabetes
•6.Intrauterine fetal death
•7.Participation in another clinical study
•8. Multiple pregnancies

发起方

department of OBstetrics, Sahlgrenska university hospital